Reporting owner · CIK 0001763494

Dube Eric M

Visual SEC Form 4 history across 1 companies, 23 transactions and 5 filings.

CEOCHIEF EXECUTIVE OFFICERTravere Therapeutics, Inc.
Open-market mix
Latest filingSep 18, 2026, 01:31 AM
Filings5Form 4 records
Buying$00 purchases
Selling$30.1M13 sales
Net value−$30.1MBuys minus sells
Companies12 securities
Most recentSep 17, 2026exercise

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.

Monthly open-market activity

Reported purchase and sale transaction counts

Buys Sells
1050-5-101Jan 252Feb 25Jan 262Feb 268Sep 26

Net value flow

Buys minus sells

Jan 25
−$208.9K
Feb 25
−$1.3M
Jan 26
$0
Feb 26
−$3.2M
Sep 26
−$25.4M

Transaction texture

Ownership and ticket size

Average P/S size$2.3M
Median P/S size$1.1M
Direct23
Indirect0
Sep 17, 2026exercise

Filing-only signals

Deterministic matches in this insider's history

Cluster Sellingpattern5Derivative Transactionfiling-context2Direct Ownershipfiling-context9Large Holdings Increaseholdings3Large Salesize3Repeat Sellerpattern310b5-1 Detectedfiling-context9

Latest Form 4 facts

Quick context from source filings

Latest transaction

sale at Travere Therapeutics, Inc. on Sep 17, 2026 valued at $441,795.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Latest sale

sale at Travere Therapeutics, Inc. on Sep 17, 2026 valued at $441,795.

Review SEC filing

Associated companies

Visual map of known reporting history

TVTXTravere Therapeutics, Inc.23 transactions · latest Sep 18, 2026, 01:31 AM

Latest insider transactions

Form 4 filings from available history. Click any column to sort; click it again to flip the order.

Dube Eric M transactions
IDTickerInsiderRoleTypeSharesValueCodeFiledTrans date
#225235TVTXDube Eric M
CEO
sale10b5-13.10k-$19.7MS09/1809/15
#225234TVTXDube Eric M
CEO
sale10b5-128.7k-$180MS09/1809/15
#225233TVTXDube Eric M
CEO
sale10b5-163.4k-$393MS09/1809/15
#225232TVTXDube Eric M
CEO
exercise10b5-195.6k$223MM09/1809/15
#38590TVTXDube Eric M
CEO
grant10b5-1303k$0A02/0401/31
#38589TVTXDube Eric M
CEO
sale10b5-133.6k-$109MS02/0402/03
#38588TVTXDube Eric M
CEO
sale10b5-166.4k-$213MS02/0402/03
#38587TVTXDube Eric M
CEO
grant10b5-1113k$0A02/0401/31
#90936TVTXDube Eric M
CEO
sale10b5-111.3k-$27.3MS02/13/202502/11/2025
#121098TVTXDube Eric M
CEO
grant10b5-1260k$0A02/05/202501/31/2025

Dube Eric M Insider Activity FAQ

SEC Form 4 context

Who is Dube Eric M?

Dube Eric M is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001763494.

Which companies has Dube Eric M reported transactions for?

Travere Therapeutics, Inc.

When was Dube Eric M's latest insider buy?

No open-market insider purchase is available for this period.

When was Dube Eric M's latest insider sale?

sale at Travere Therapeutics, Inc. on Sep 17, 2026 valued at $441,795.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.